Celgene Corp. (NASDAQ:CELG) – Research analysts at Leerink Swann reduced their Q3 2016 EPS estimates for Celgene Corp. in a report issued on Friday. Leerink Swann analyst G. Porges now anticipates that the brokerage will earn $1.30 per share for the quarter, down from their prior estimate of $1.32. Leerink Swann currently has a “Market Perform” rating and a $135.00 target price on the stock. Leerink Swann also issued estimates for Celgene Corp.’s Q4 2016 earnings at $1.39 EPS.

Celgene Corp. (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.05. Celgene Corp. had a net margin of 18.95% and a return on equity of 67.06%. The company earned $2.74 billion during the quarter, compared to analysts’ expectations of $2.70 billion. During the same period in the previous year, the company earned $1.23 EPS. The business’s quarterly revenue was up 20.9% compared to the same quarter last year.

Other analysts also recently issued reports about the stock. Canaccord Genuity set a $156.00 price target on shares of Celgene Corp. and gave the company a “buy” rating in a report on Sunday, September 18th. Zacks Investment Research raised shares of Celgene Corp. from a “hold” rating to a “buy” rating and set a $117.00 price target for the company in a report on Friday. Morgan Stanley reaffirmed a “hold” rating on shares of Celgene Corp. in a report on Thursday, June 30th. Cowen and Company reaffirmed a “buy” rating and set a $150.00 price objective on shares of Celgene Corp. in a report on Thursday, July 28th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $140.00 price objective on shares of Celgene Corp. in a report on Wednesday, June 29th. Three research analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $137.44.

Shares of Celgene Corp. (NASDAQ:CELG) opened at 104.07 on Monday. Celgene Corp. has a 52 week low of $93.05 and a 52 week high of $128.39. The stock has a market capitalization of $80.67 billion, a PE ratio of 43.99 and a beta of 1.49. The stock’s 50 day moving average is $107.29 and its 200 day moving average is $105.50.

In other news, Director Michael A. Friedman sold 56,116 shares of the business’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $103.66, for a total value of $5,816,984.56. Following the sale, the director now owns 50,000 shares of the company’s stock, valued at $5,183,000. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gilla Kaplan sold 9,710 shares of the business’s stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $106.44, for a total transaction of $1,033,532.40. Following the transaction, the director now owns 72,142 shares in the company, valued at $7,678,794.48. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of CELG. Park National Corp OH increased its position in shares of Celgene Corp. by 0.4% in the third quarter. Park National Corp OH now owns 3,158 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 12 shares during the last quarter. Ropes Wealth Advisors LLC increased its position in shares of Celgene Corp. by 0.9% in the first quarter. Ropes Wealth Advisors LLC now owns 1,477 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 13 shares during the last quarter. Kings Point Capital Management increased its position in shares of Celgene Corp. by 1.7% in the first quarter. Kings Point Capital Management now owns 1,316 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 22 shares during the last quarter. Pitcairn Co. increased its position in shares of Celgene Corp. by 0.8% in the second quarter. Pitcairn Co. now owns 4,948 shares of the biopharmaceutical company’s stock worth $488,000 after buying an additional 38 shares during the last quarter. Finally, Meristem LLP increased its position in shares of Celgene Corp. by 1.7% in the second quarter. Meristem LLP now owns 2,391 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 40 shares during the last quarter. Institutional investors and hedge funds own 77.75% of the company’s stock.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.